BRISTOL-MYERS Squibb has welcomed the TGA registration of Optivo in combination with Yervoy for the treatment of patients with advanced kidney cancer.
It's the first combination immunotherapy for the condition, with the approval granted under the TGA's new Priority Review process which aims to review medicines within 150 working days.
The approval is also the tenth indication for Opdivo across six cancer types.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jul 18
